GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Cyclically Adjusted FCF per Share

Emergent BioSolutions (STU:ER4) Cyclically Adjusted FCF per Share : €0.80 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Emergent BioSolutions's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-1.294. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.80 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Emergent BioSolutions's average Cyclically Adjusted FCF Growth Rate was -28.90% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -12.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 12.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Emergent BioSolutions was 43.60% per year. The lowest was -12.00% per year. And the median was 24.10% per year.

As of today (2024-05-26), Emergent BioSolutions's current stock price is €4.313. Emergent BioSolutions's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.80. Emergent BioSolutions's Cyclically Adjusted Price-to-FCF of today is 5.39.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Emergent BioSolutions was 190.15. The lowest was 1.81. And the median was 77.17.


Emergent BioSolutions Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Emergent BioSolutions's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Cyclically Adjusted FCF per Share Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.13 1.53 1.41 0.79

Emergent BioSolutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.82 0.75 0.79 0.80

Competitive Comparison of Emergent BioSolutions's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted Price-to-FCF falls into.



Emergent BioSolutions Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Emergent BioSolutions's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.294/131.7762*131.7762
=-1.294

Current CPI (Mar. 2024) = 131.7762.

Emergent BioSolutions Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.115 100.560 0.151
201409 1.228 100.428 1.611
201412 0.769 99.070 1.023
201503 -1.825 99.621 -2.414
201506 -0.152 100.684 -0.199
201509 1.693 100.392 2.222
201512 -0.192 99.792 -0.254
201603 0.445 100.470 0.584
201606 -0.510 101.688 -0.661
201609 0.182 101.861 0.235
201612 -0.609 101.863 -0.788
201703 0.402 102.862 0.515
201706 0.794 103.349 1.012
201709 0.368 104.136 0.466
201712 1.080 104.011 1.368
201803 -0.206 105.290 -0.258
201806 0.351 106.317 0.435
201809 2.461 106.507 3.045
201812 -3.154 105.998 -3.921
201903 1.442 107.251 1.772
201906 -0.858 108.070 -1.046
201909 -0.319 108.329 -0.388
201912 1.469 108.420 1.785
202003 0.585 108.902 0.708
202006 1.540 108.767 1.866
202009 0.930 109.815 1.116
202012 3.160 109.897 3.789
202103 -0.786 111.754 -0.927
202106 -1.486 114.631 -1.708
202109 -0.609 115.734 -0.693
202112 4.670 117.630 5.232
202203 -1.245 121.301 -1.353
202206 -0.903 125.017 -0.952
202209 -2.063 125.227 -2.171
202212 1.312 125.222 1.381
202303 -3.704 127.348 -3.833
202306 -2.310 128.729 -2.365
202309 0.857 129.860 0.870
202312 0.364 129.419 0.371
202403 -1.294 131.776 -1.294

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Emergent BioSolutions  (STU:ER4) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Emergent BioSolutions's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=4.313/0.8
=5.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Emergent BioSolutions was 190.15. The lowest was 1.81. And the median was 77.17.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Emergent BioSolutions Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions (STU:ER4) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines